Research programme: antibacterial protein-based therapeutics - Phico Therapeutics

Drug Profile

Research programme: antibacterial protein-based therapeutics - Phico Therapeutics

Alternative Names: PT2.0; PT3; PT3.33; PT3.X; PT4.0; PTS3.2; SASP programme; SASPject™ PT3.1; SASPject™ PT3.X; SASPject™PT2.0; SASPject™PT4.0; SASPject™PTS3.2

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phico Therapeutics
  • Class Peptides
  • Mechanism of Action Bacterial DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom (IV, Injection)
  • 09 Mar 2015 Preclinical development is underway in United Kingdom
  • 12 Sep 2012 Pharmacodynamics data from preclinical studies in Bacterial infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top